NCT07372820Recruiting
METABolic Deterioration in HTX Determines Outcomes
METAB-HTX: Prospective, Longitudinal Cohort Study Evaluationg Cardiac and Systemic Metabolism After Heart Transplantation
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
METAB-HTX is a prospective, longitudinal cohort study evaluating cardiac and systemic metabolism in heart transplant recipients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 270 (estimated)
- First submitted
- 20 Jan 2025
- Start date
- 24 Jul 2025
- Primary completion date
- 1 Apr 2030
- Lead sponsor
- Heinrich-Heine University, Duesseldorf
- Diseases
- Heart failure, Type 2 diabetes
- NCT number
- NCT07372820
What you commit to
- Study type: Observational
- Planned participants: 270
- From 24 Jul 2025 to the primary completion date, 1 Apr 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Absence of informed consent
Who the study is looking for
- Age: ≥ 18 years
- Planned or already conducted heart transplantation
- Informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University-Hospital Düsseldorf Division of Cardiology, Pneumology and Angiology Coordinator of this site? Confirm its status | Düsseldorf | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.